Management of cardiac sarcoidosis: A clinical consensus statement of the Heart Failure Association, the European Association of Cardiovascular Imaging, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Heart Rhythm Association of the ESC
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10483123" target="_blank" >RIV/00064165:_____/24:10483123 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10483123
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=haI09C3KI1" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=haI09C3KI1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/eurheartj/ehae356" target="_blank" >10.1093/eurheartj/ehae356</a>
Alternative languages
Result language
angličtina
Original language name
Management of cardiac sarcoidosis: A clinical consensus statement of the Heart Failure Association, the European Association of Cardiovascular Imaging, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Heart Rhythm Association of the ESC
Original language description
Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored. Graphical Abstract The multi-disciplinary team based approach to the diagnosis and treatment of cardiac sarcoidosis. CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; FDG-PET, fluorodeoxyglucose positron emission tomography; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardiac defibrillator; MDT, multidisciplinary team; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricle; TNF, tumour necrosis factor.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Heart Journal
ISSN
0195-668X
e-ISSN
1522-9645
Volume of the periodical
45
Issue of the periodical within the volume
30
Country of publishing house
GB - UNITED KINGDOM
Number of pages
30
Pages from-to
2697-2726
UT code for WoS article
001254378800001
EID of the result in the Scopus database
2-s2.0-85200408671